Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 39,260 | -1,03 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
CSPC PHARMA | 0,752 | +3,73 % | CSPC Pharmaceutical Group-Aktie kann Vortagsniveau nicht halten (0,686 €) | Im Minus liegt zur Stunde die Aktie der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,69 Euro. An der Börse liegt die CSPC Pharmaceutical Group-Aktie aktuell im Minus. Die Aktie verbilligte... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 15,540 | +0,32 % | Aktien New York: Indizes bauen Gewinne aus - Inflationsdaten im Fokus | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben nach einem trägen Wochenstart am Dienstag zugelegt. Allerdings reagierten die Aktienkurse erst mit einiger Verzögerung positiv auf US-Inflationsdaten... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,418 | -1,12 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update | Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 181,35 | -5,10 % | Madrigal Pharmaceuticals, Inc.: Madrigal Statement on the Passing of Dr. Stephen Harrison | ||
CATALYST PHARMACEUTICALS | 13,855 | -1,98 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
ENZON PHARMACEUTICALS | 0,056 | -3,45 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.11.2023 | The following instruments on Boerse Frankfurt do have their last trading day on 17.11.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.11.2023ISIN NameAU000000DCN6 DACIAN... ► Artikel lesen | |
OCUPHIRE PHARMA | 1,448 | +1,54 % | Ocuphire Pharma: First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery | LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP)... ► Artikel lesen | |
DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information | Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical... ► Artikel lesen | |
VIRACTA THERAPEUTICS | 0,765 | -1,92 % | Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from... ► Artikel lesen | |
SAVARA | 3,840 | -3,03 % | Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update | LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth... ► Artikel lesen | |
GALECTIN THERAPEUTICS | 2,980 | -1,97 % | Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying | ||
BIODEXA PHARMACEUTICALS | 0,680 | -2,16 % | Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023 | 19 April 2024 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals... ► Artikel lesen |